Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Briesewitz

Blood

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Blood|June 1, 2007
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemiaLisheng Wang, Jie Wang, Bradley W Blaser, et al.
Blood|December 9, 2008
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cellsDon M Benson, Jianhua Yu, Brian Becknell, et al.
Blood|May 4, 2007
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemiaMichael A Caligiuri, Roger Briesewitz, Jianhua Yu, et al.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Blood|June 1, 2007
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemiaLisheng Wang, Jie Wang, Bradley W Blaser, et al.
Blood|December 9, 2008
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cellsDon M Benson, Jianhua Yu, Brian Becknell, et al.
Blood|May 4, 2007
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemiaMichael A Caligiuri, Roger Briesewitz, Jianhua Yu, et al.
Blood|August 9, 2013
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesJoshua J Oaks, Ramasamy Santhanam, Christopher J Walker, et al.
Pageof 1